Диссертация (1139649), страница 50
Текст из файла (страница 50)
- P. 503–511.244.Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott’s disease)following intravesical BCG therapy / I.S. Aljada, J.K. Crane, N. Corriere [et al.]// J. Clin. Microbiology. – 1999. – Vol. 37, N 6. – P. 2106–2108.245.Mycolic acid patterns of representatives of Mycobacterium Bovis BCG / D.Minnikin, J.H. Pariett, M. Magnusson [et l.] // J. Gen. microbiol. - 1984. - Vol.130.
- P. 2733–2736.246.Nakatani, H. Development of vaccination policy in Japan: current issuesand policy directions / H. Nakatani, T. Sano, T. Iuchi // Japan. J. Infect. Dis.2002. – Vol. 55, N 4. – P. 101–111.247.National study of adverse reactions after vaccination with bacille Calmette-309Guerin / F.M. Turnbull, P.B. McIntyre, H.M. Achat [et al.] // Clin. Infect. Dis. –2002. - Vol.
34, N 4. - P. 447–453.248.Norouzi, S. Aghamohammadi And, Mamishi S, D. Rosenzweig, Rezai N.Calmette-Guerin(BCG)Complicationsassociatedwithprimaryimmunodeficiencies / S. Norouzi. – J. Infect. – 2012. – Vol. 14. – P. 543 - 554.249.Nuttall, J.J.C. BCG Vaccination in HIV-Infected Children / J.J.C. Nuttall,B.S.
Eley // Tuberc. Res. Treat. – 2011. – Vol. 2011. – P. 712–736.250.Observed rate of vaccine reactions of Bacillus Calmette-Guerin (BCG)vaccine: inform. sheet / World Health Organ. - Geneva, World HealthOrganization, 2012. – Aprel. - 5 p.251.Observed Rate of Vaccine Reactions Bacille Calmette-Guérin (Bcg)Vaccine Global Vaccine Safety, Immunization, Vaccines and Biologicals: sheet/ WorldHealthOrgan.Geneva,2012.-http://www.who.int/vaccine_safety/initiative/tools/BCG_Vaccine_rates_information_sheet.pdf252.Optimal models to evaluate the protective efficacy of tuberculosis vaccines/ J.F.
Griffin, D.N. Chin, C.R. Rodgers, C.G. Mackintosh // Tuberculosis. – 2001.– Vol. 81, N 1-2. – P. 133–139.253.Osteitis after newborn vaccination with three different Bacillus Caimette-Guerin vaccines / L. Kroger, E. Brander, M. Korppi [et al.] // Pediatr. Infect. Dis.J. - 1994. - Vol. 13, № 2.
- P. 113–116.254.Osteomyelitis of the humerus complicating BCG vaccination / S. Segal,A.J. Pollard, C. Watts [et al.] // Arch. Dis. Child. - 2006. – Vol. 91, N 3. - P. 244–244.255.Ottenhoff, T.H. Vaccines against Tuberculosis: Where Are We andWhere Do We Need to Go? // T.H. Ottenhoff, S.H. Kaufmann. - PLoSPathog. – 2012. – Vol. 8, N 5. – http://www.ncbi.nlm.nih.gov/pubmed256.Plotkin, S.A. Vaccines / S.A. Plotkin, W.A. Orenstein, P.A. Offit. - 6thEdn. – Philadelphia: Elsevier Saunders, 2013. – 1578 p.257.Pontecorvo, M. Vaccines and procedures / M. Pontecorvo // Vaccines Sera310Immunoglobulins.
- Torino: Minerva Medica, 1985. – P. 18–19.258.Presumed BCG infection in a boy with chronic granulomatous disease.1984. A report of a case and a review of literature / Y. Kobayashi, Y. Komazawa,M. Kpbayashi [et al.] // Clin. Pediatr. - Vol. 23. – P. 596 - 589.259.Price, J. BCG vaccination / J. Price // Arch. Dis. Child. - 1982.
- Vol. 57, №7. - P. 485–486.260.Protection by BCG vaccine against tuberculosis: a systematic review ofrandomized controlled trials / P. Mangtani, I. Abubkar, C. Ariti [et al.] // Clin.Infect. Dis. – 2014. – Vol. 58, N 4. – P. 470–480.261.Protective efficacy of neonatal Bacillus Calmette-Guerin vaccinationagainst tuberculosis / A. Sirivanin., T.
Chotpitavasunondh, S. Suwanjutha [et al.]// Pediat. Infec. Dis. J. – 1991. – Vol. 1, № 1. – P. 359–365.262.Rates of adverse reactions to first and second doses of BCG vaccination:results of a large community trial in Brazilian schoolchildren / I. Dourado, M.H.Rios, S.M.
Pereira [et al.] // Int. J. Tuberc. Lung Dis. – 2003. - Vol. 7, N 4. – P.399–402.263.Raviglione, M.C. WHO’s new Stop TB Strategy / M.C. Raviglione, M.W.Uplekar // Lancet. - 2006. – Vol. 367. – P. 952–955.264.ResistantMycobacteriumbovisbacillusCalmette-Guerindisease:implications for management of bacillus Calmette-Guerin disease in HumanImmunodeficiency Virus-infected children / A.C. Hesseling, H.S.
Schaaf, T.Victor [et al.] // Pediatr. Infect. Dis. J. – 2004. - Vol. 23, № 5. – P. 476 - 479.265.Report of anIUIS Scientific Committee.InternationalUnionof Immunological Societies // Clin. Exp. Immunol. – 1999. – Vol. 118. – P. 1-28.266.Revised BCG vaccination guidelines for infants at risk for HIV infection //Wkly Epidemiol. Rec. – 2007. – Vol. 82.
– P. 193–196.267.Rodrigues, L. BCG vaccination in the first year of life protects children ofIndian subcontinent ethnic origin against tuberculosis in England / L. Rodriegues,O. Gill, P. Smith // J. Epidem. Commun. Health. - 1991. - Vol. 45, № 1. - P. 78–80.311268.Romanus, V. First experience with BCG discontinuation in Europe.Experience in Sweden 15 years after stopping general BCG vaccination at birth /V. Romanus // Bull.
Int. Union Tuberc. Lung Dis.- 1990. – Vol. 65. – P. 32–35.269.Rosenthal, S. BCG vaccine: Tuberculosis-Cancer / S. Rosenthal.-Massachusets, 1980. – 217 p.270.Safety and efficacy of MVA85A, a new tuberculosis vaccine, infantspreviously vaccinated with BCG: a randomized, placebo-controlled phase 2b trial/ M.D.
Tameris, M. Hatherill, B.S. Landry [et al.] // Lancet. - 2013. – Vol. 381. –P. 1021–1028.271.Safety and immunogenicity of a candidate tuberculosis vaccine MVA85Adelivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind,randomised controlled trial // I. Satti, J.
Meyer, S. Harris [et al.] // Lancet Infect.Dis. – 2014. – Vol. 14. – P. 939–946.272.Safety and immunogenicity of Bacillus Calmette-Guerin vaccine inchildren born to HIV-1 infected women / P. Thaithumyanon, U. Thisyakorn, S.Punnahitanada [et al.] // Southeast. Asian J. Trop. Med.
Public Health. – 2000. Vol. 31, N 3. – P. 482–486.273.Scaling up interventions to achieve global tuberculosis control: progressand new developments / M. Raviglione, B. Marais, K. Floyd [et al.] // Lancet. –2012. – Vol. 379. – P. 1902–1913.274.Schroeder,H.W.GeneticsofIgAdeficiencyandcommonimmunodeficiency / H.W. Schroeder // Clin. Rev. Allergy Immunol.
– 2000. –Vol. 19. – P. 127–140.275.Schulze, W. BCG-osteitis / W. Schulze // Pneumologie. - 1990. - Bd. 44. -S. 484–485.276.Second IUATLD Stady on complications induced by intradermal BCG-vaccination / A. Lotte, O. Wasz-Hockert, N. Poisson [et al.] // Bull. Int. UnionTuberc. Lung.
Dis. – 1988. - Vol. 63, № 2. - P. 47–59.277.Smith, D. Protective effect of BCG in experimental tuberculosis / D. Smith// Advanc. Tuberc. Res. – 1985. - Vol. 22. – P. 1–99.312278.Smith, H.G. Retrospective assessment of the effectiveness of the BCGvaccination against tuberculosis using case-control method / H.G. Smith //Tubercle. – 1982. – Vol. 62. - P. 23–35.279.Smith P.A., Wittenberg D.F. Disseminated BCG infection in a child withchronic granulomatous disease.
A case report // S. Afr. Med. J. – 1984. Vol.65(20). – Р. 821–822.280.Specific T cell frequency and cytokine expression profile do not correlatewith protection against tuberculosis after bacillus Calmette-Guerin vaccination ofnewborns / B. Kagina, B. Abel, T. Scriba [et al.] // Amer. J. Resp. Crit Care Med.– 2010. – Vol. 182. – P. 1073–1079.281.Springett, V. BCG vaccination of schoolchildren in England and Wales / V.Springett, I. Sutherland // Thorax. - 1990. - Vol. 45, № 2. - P.
83 - 88.282.Starke, J. R. Prevention of tuberculosis / J. Strake // Semin. resp. Infect. -1989. - Vol. 4, № 4. - P. 321–324.283.Status of Vaccine Research and Development of Vaccines for TuberculosisPreparedforWHOPD-VAC.-2014.-https://docviewer.yandex.ru/?url=http%3A%2F%2Fwww.who.int%2Fimmunization%2Fresearch%2Fmeetings_workshops%2FTuberculosis_VaccineRD_Sept2014.pdf&name=Tuberculosis_VaccineRD_Sept2014.pdf&lang=en&c=57deeebcdb18.284.Stop TB Partnership and the World Health Organization. GlobalPlan to Stop TB, 2011–2015: Transforming the Fight towards Eliminationof Tuberculosis / World Health Organ.
– Geneva, 2010. - Available from:http://www.stoptb.org/assets/documents/global/plan/TB_GlobalPlanToStopTB2011–2015.pdf.285.Stop TB Partnership (2006) The Global Plan to Stop TB, 2006–2015.Actions for life: towards a world free of tuberculosis // Int. J. Tuberc. Lung Dis. –2006. – Vol. 10. – P.
240–241.286.Su, W.-J. Utility of PCR assays for rapid diagnosis of BCG infection inchildren. International / W.-J. Su, C.-Y. Hung, R.-P. Perng // J. Tuberc. Lung Dis.– 2001. – Vol. 5, N 4. – P. 380–384.313287.Surgical pathology of the lung in chronic granulomatous disease / C.A.Moskaluk, H.W. Pogrebniak, H.I. Pass [et al.] // Amer. J. Clin. Pathol. – 1994. Vol.
102. - P. 684–691.288.Survey of BCG vaccination policy in Europe: 1994–1996 / L. Trnka, D.Dankova, J. Zitova [et al.] // Bull. World Health Organ. – 1998. – Vol. 76. – P. 85–91.289.Systematic review and meta-analysis of the current evidence on theduration of protection by bacillus Calmette-Guérin vaccination againsttuberculosis / I. Abubakar, L. Pimpin, C. Ariti [et al.] // Health technol.
Assess. –2013. – Vol. 17, N 37. – P. 13–72.290.Szczuka, I. Adverse events following immunization with BCG vaccine inPoland 1994-2000 / I. Szczuka // Przegl. Epidemiol. – 2002. - Vol. 56, N 2. – P.205–216.291.Tan, H. Scrofuloderma after BCG vaccination / H. Tan, A. Karakuzu, A.Arik // Pediatr.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
